organization · Reporting owner
Bill & Melinda Gates Foundation
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Atreca, Inc.
Report date June 24, 2019 · Filed June 24, 2019
Section 16 reporting ended · disclosed 2019-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,396,644 |
Reported balance
After 2019-06-24 transaction · row 1
1 source rowRow 1 · 2019-06-24 · Conversion · Acquired 1,396,644 · Balance 1,396,644 F1: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-24 · Conversion · Disposed 1,396,644 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock.
Liquidia Technologies Inc
Report date July 30, 2018 · Filed August 01, 2018
Section 16 reporting ended · disclosed 2018-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 797,073 |
Reported balance
After 2018-07-30 transaction · row 1
1 source rowRow 1 · 2018-07-30 · Conversion · Acquired 797,073 · Balance 797,073 F1: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-30 · Conversion · Disposed 11,286,115 · Balance 0 F1: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
Vir Biotechnology, Inc.
Report date October 16, 2019 · Filed October 16, 2019
Section 16 reporting ended · disclosed 2019-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,777,777 |
Reported balance
After 2019-10-16 transaction · row 1
1 source rowRow 1 · 2019-10-16 · Conversion · Acquired 2,777,777 · Balance 2,777,777 F1: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. |
| Series A-1 convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-16 · Conversion · Disposed 2,222,222 · Balance 0 F1: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-16 · Conversion · Disposed 555,555 · Balance 0 F1: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock.
X4 Pharmaceuticals, Inc
Report date November 20, 2017 · Filed November 21, 2017
Section 16 reporting ended · disclosed 2017-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 722,179 |
Reported balance
After 2017-11-20 transaction · row 1
1 source rowRow 1 · 2017-11-20 · Conversion · Acquired 722,179 · Balance 722,179 F1: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-20 · Conversion · Disposed 2,464,799 · Balance 0 F1: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2019 Filed Oct 16, 2019 20:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B convertible preferred stock · Derivative | 555,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001252 · form4.xml · derivative · entry 3 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 555,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 convertible preferred stock · Derivative | 2,222,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001252 · form4.xml · derivative · entry 2 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,222,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:31 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 2,777,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-001252 · form4.xml · nonDerivative · entry 1 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,777,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. F1 · price: Upon closing of the Issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 17:23 UTC | Atreca, Inc. BCEL · Entity 91940 | ConversionSeries A Preferred Stock · Derivative | 1,396,644 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-000930 · form4.xml · derivative · entry 2 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,396,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 17:23 UTC | Atreca, Inc. BCEL · Entity 91940 | ConversionClass A Common Stock | 1,396,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-19-000930 · form4.xml · nonDerivative · entry 1 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. F1 · price: Upon closing of the issuer's initial public offering, the Series A Preferred Stock converted automatically into Class A Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A Preferred Stock. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:26 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionSeries C-1 Preferred Stock · Derivative | 11,286,115 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-18-000882 · form4.xml · derivative · entry 2 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 797,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:26 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionCommon Stock | 797,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-18-000882 · form4.xml · nonDerivative · entry 1 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of Series C-1 Preferred Stock, par value $0.001 per share, had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0706-for-1 basis immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 00:09 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | ConversionSeries D Convertible Preferred Stock · Derivative | 2,464,799 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-17-001103 · form4.xml · derivative · entry 2 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 722,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. F1 · derivative.exercise_date: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. F1 · derivative.expiration_date: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 00:09 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | ConversionCommon Stock | 722,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-17-001103 · form4.xml · nonDerivative · entry 1 Bill & Melinda Gates Foundation · CIK 0001663801 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. F1 · price: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.